SCHEMBL13748639

SCHEMBL13748639

CC(C)c1nc(CN(C)C(=O)NC(C(=O)NC(Cc2ccccc2)CC(O)C(N)Cc2ccccc2)C(C)C)cs1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 19/20 0.69
CYP2D6 P10635 7/20 0.69
CYP2C9 P11712 3/20 0.69
CYP2C19 P33261 3/20 0.69
MEN1 O00255 1/20 0.69
SLC22A2 O15244 1/20 0.69
SLC22A1 O15245 1/20 0.69
ABCC3 O15438 1/20 0.69
ABCC4 O15439 1/20 0.69
MLNR O43193 1/20 0.69
NR1I2 O75469 1/20 0.69
SLCO2B1 O94956 1/20 0.69
ABCB11 O95342 1/20 0.69
ALDH1A1 P00352 1/20 0.69
PGR P06401 1/20 0.69
ABCB1 P08183 1/20 0.69
HTR1A P08908 1/20 0.69
ADRA2A P08913 1/20 0.69
ADORA3 P0DMS8 1/20 0.69
MAPT P10636 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13749205 1.00 CYP3A4 (0.69) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL7302347 0.91 CA2 (0.60) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL8269408 0.91 CYP3A4 (0.77) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL2913540 0.91 CYP3A4 (0.77) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL3304792 0.89 CYP3A4 (0.75) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL794553 0.89 CYP3A4 (0.75) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL3716311 0.89 CYP3A4 (0.75) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL2736323 0.89 CYP3A4 (0.72) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL2736324 0.88 CYP3A4 (0.77) CYP3A4CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL13240262 0.87 CYP3A4 (0.69) CYP3A4CYP2D6CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501792-B2 Treating cancer with desthiazolyl ritonavir NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-06 US disclosed
US-20120329841-A1 TREATING CANCER WITH DESTHIAZOLYL RITONAVIR NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-12-27 US disclosed
WO-2009105430-A1 TREATING CANCER WITH DESTHIAZOLYL RITONAVIR REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329841-A1 TREATING CANCER WITH DESTHIAZOLYL RITONAVIR DUT, DHCR7, BRCA1 CYP3A4 21/4885CYP2D6 35/4885CYP2C9 67/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.